Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
December 11 2024 - 8:00AM
UK Regulatory
Teva Announces New Patient Access Program with Direct Relief to
Provide Access to Inhalers for Uninsured Patients
- Teva to provide
two generic inhaler products to Direct Relief for its
network of free and charitable
clinics
- The program, launching this
month, will run for a minimum of three years
PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva
Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA), announced today the launch
of a new patient access program, in partnership with Direct Relief,
to supply inhalers to eligible patients in the United States free
of charge.
“In the United States, while 93% of Teva’s inhaler medicines are
generic products with access at lower prices – particularly for
insured patients – there still remain uninsured patients who cannot
access affordable generic inhalers,” said Chris Fox, Executive Vice
President, U.S. Commercial at Teva. “The aim of this program is to
help address an unmet need in underserved communities nationwide,
enhancing patient access to safe and affordable medicines delivered
via inhalers, including both maintenance and rescue inhalers.”
Teva will make two inhaler products available through this
program: generic versions of the AirDuo®RespiClick® (fluticasone
propionate/salmeterol xinafoate maintenance inhaler) and ProAir®
HFA (albuterol sulfate rescue inhaler). Teva will donate the
inhalers to Direct Relief for distribution by request to free &
charitable clinics, to then be dispensed to uninsured patients
served by these clinics.
"Direct Relief is deeply grateful to Teva for this critical
donation which will connect patients with respiratory treatments
they otherwise would not have access to," said Katie Lewis,
Regional Director, U.S. Programs for Direct Relief. "Free and
charitable clinics offer quality care for underserved communities,
and this donation will allow them to reach even more patients with
these medications."
The program will continue for a minimum of three years to ensure
reliable and continuous supply to these patients. In addition to
donating the inhalers, Teva will make a cash donation to Direct
Relief to cover the costs of administering this program.
Direct Relief, Teva’s long-time partner on access to medicines
programs in the U.S. and around the world, is a nonprofit
humanitarian organization that provides medical resources to
resource-poor communities. It operates, by its own account, the
largest charitable medicine program in the United States. Through
its network, Direct Relief supports the dispensing of high-quality,
no-cost medicines to low-income, uninsured patients at the point of
care, thereby facilitating patient access to necessary
medicines.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global pharmaceutical leader with a category-defying portfolio,
harnessing our generics expertise and stepping up innovation to
continue the momentum behind the discovery, delivery, and expanded
development of modern medicine. For over 120 years, Teva's
commitment to bettering health has never wavered. Today, the
company’s global network of capabilities enables its ~37,000
employees across 58 markets to push the boundaries of scientific
innovation and deliver quality medicines to help improve health
outcomes of millions of patients every day. To learn more about how
Teva is all in for better health, visit
www.tevapharm.com.
Cautionary Note Regarding
Forward-Looking Statements
This document and the
presentation at the conference may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, which are based on management’s current beliefs
and expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: our to successfully make our
two inhaler products available through the new patient access
program; our ability to successfully compete in the marketplace
including our ability to successfully execute our Pivot to Growth
strategy; our substantial indebtedness; our business and operations
in general including the impact of global economic conditions and
other macroeconomic developments and the governmental and societal
responses thereto; compliance, regulatory and litigation matters;
other financial and economic risks; and other factors discussed in
our Quarterly Report on Form 10-Q for the third quarter of 2024 and
in our Annual Report on Form 10-K for the year ended December 31,
2023, including in the sections captioned "Risk Factors.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or
otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
IR Contacts
|
|
|
TevaIR@Tevapharm.com
|
|
|
|
|
|
|
|
|
PR Contacts
|
United States
|
Kelley Dougherty
|
(973) 658-0237
|
|
Israel
|
Yonatan Beker
Eden Klein
|
(973) 264 7378
972 (3) 906-2645
|
|
|
|
|
Teva Pharmaceutical Indu... (TG:TEV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Teva Pharmaceutical Indu... (TG:TEV)
Historical Stock Chart
From Dec 2023 to Dec 2024